YCC receives $175k research grant from Breast Cancer Research Foundation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Yale Cancer Center has received a one-year, $175,000 research grant from the Breast Cancer Research Foundation to study reducing re-excisions for breast conserving therapy for women following surgery for breast cancer.

Principal investigator of the grant, Mehra Golshan, joins three other YCC BCRF funded researchers: Melinda Irwin, Lajos Pusztai, and David Rimm.

This grant reflects the need to find ways to reduce unnecessary re-excisions during their treatment that leads to delay in initiation of adjuvant therapy, increase in costs, negative psychological impact, more women choosing mastectomy and higher infection rates,” Golshan, deputy chief medical officer for Surgical Services at Smilow Cancer Hospital and YCC, and interim director of the Breast Center at Smilow Cancer Hospital, said in a statement.

During breast conserving surgery, the need for re-excision occurs between 15-25% of time. When removing a breast tumor, surgeons strive for clean margins. That means targeting not only the tumor, but also excising the surrounding border of tissue. Margins are clean if no cancer cells are found at the outer edge of that tissue.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login